On Friday, Capricor Therapeutics CAPR announced 3-year safety and efficacy results from its ongoing HOPE-2 open-label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disease that causes progressive muscle weakness and degeneration. Cardiac and orthopedic complications, including scoliosis...